PROGRESS IN ALZHEIMER'S DISEASE RESEARCH
Recruitment for Phase II clinical trial of Alzheimer's drug PRI-002 successfully completed
Priavoid GmbH and PRInnovation GmbH have successfully completed the recruitment for the clinical Phase II study PRImus-AD, which investigates the drug candidate PRI-002 for the treatment of Alzheimer's disease in terms of safety and efficacy.
The recruitment phase was completed on schedule - a significant milestone that underlines the exceptional cooperation of all partners involved.
In total, 40 test centers were activated in six European countries last year, 540 patients were screened and 304 patients were successfully enrolled in the study. The PRImus-AD study aims to evaluate the safety and efficacy of PRI-002 in patients at an early stage of Alzheimer's disease. This innovative first-in-class drug targets the causes of neuronal destruction in Alzheimer's disease based on a purely physical mechanism of action. This approach differs fundamentally from antibody-based therapies and aims to ensure a safe and disease-modifying effect.
PRI-002 has considerable advantages over previous therapies, especially antibody therapies directed against protein deposits. With PRI-002, there is no risk of brain swelling during therapy, which means that regular MRI examinations are no longer necessary,
explains Prof. Oliver Peters, MD, Medical Director of the study. In addition, PRI-002 can be easily taken orally as a capsule and does not have to be administered as an infusion by a doctor.
The successful completion of recruitment demonstrates a tremendous achievement and great commitment from everyone involved,
says Dr. Dagmar Jürgens, Director of Clinical Development at Priavoid GmbH. We are hopeful about the future of the program.
ABOUT PRIMUS-AD
The study is being conducted by PRInnovation GmbH as the sponsor and funded by SPRIND. The results are expected in the second half of 2026. If the results are positive, a phase III approval study will then be launched with a pharmaceutical partner.
